抗体-药物结合物-进化和前景
Adriana Aurelia Chis1, Carmen Maximiliana Dobrea1, Anca Maria Arseniu1
1Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania.
International journal of molecular sciences
|July 13, 2024
概括
抗体-药物合物 (ADC) 是一种有前途的癌症治疗方法,它将向药物输送与降低毒性相结合. 这篇评论详细介绍了它们的化学结构,药理学,临床试验和未来的挑战.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 抗瘤疗法旨在提高癌症治疗的疗效,减少副作用.
- 抗体-药物合物 (ADC) 是癌症治疗中向药物输送的先进策略.
研究的目的:
- 审查抗体-药物联合体 (ADC) 的各种方面.
- 讨论ADC的化学和药理学观点,包括它们的结构,结合,发展,作用,临床试验,安全性和未来的挑战.
主要方法:
- 审查关于抗体与药物合物的现有文献.
- 对ADC组件的分析:单克隆抗体,链接器和有效载荷.
- 讨论临床试验数据,安全概况和未来开发策略.
主要成果:
- ADCs为癌症治疗提供了有针对性的方法,提高了药物的疗效,并最大限度地降低了全身毒性.
- 关键的结构成分包括单克隆抗体 (例如,特拉斯图祖马布),各种链接剂和强大的细胞毒性有效载荷 (例如,多克索鲁比辛,埃姆坦辛).
- 许多正在进行的临床试验支持对ADC治疗成功的高期望.
结论:
- ADCs代表了抗瘤疗法的重大进步.
- 解决开发,安全和有效性方面的挑战对于最大限度地发挥ADC的潜力至关重要.
- 未来的研究将专注于克服目前的局限性,并扩大ADC在癌症治疗中的应用.
关键词:
抗体 药物联合体 抗体 药物联合体癌症 癌症 癌症 癌症 癌症临床试验中的临床试验.细胞毒性的有效载荷有效性 有效性 有效性.链接器是一个链接器.这是一种单克隆抗体.在安全方面,安全是安全的.有针对性的治疗.更多相关视频
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
7.6K
10:35Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
Published on: February 5, 2021
3.4K
相关概念视频
Antibody Structure and Classes
871
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
871
Antibody Actions
1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Antibody Structure
59.8K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
59.8K
Phase II Conjugation Reactions: Overview
187
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
187
Hybridoma Technology
14.4K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.4K
Affinity and Avidity
35.9K
Overview
35.9K
